Actimed Therapeutics is a biotechnology company focused on the discovery and development of innovative treatments for musculoskeletal diseases. The company leverages its expertise in the field of regenerative medicine to address the unmet medical needs in orthopedics, with a particular emphasis on developing therapies that promote the repair and regeneration of damaged tissues.

Actimed Therapeutics

ACTIMED THERAPEUTICS LTD is a company based out of the United Kingdom.

Mankind Pharma

ACTIMED THERAPEUTICS

We’re supporting International Women and Girls in Science Day! 🔬
 
Join us in celebrating the incredible contributions of our talented female staff at Actimed, whose dedication and passion play a pivotal role in driving innovation.
 
We’re proud to be an inclusive and fair employer, and our phenomenal female staff shine in various roles across the company.
 
Here's to not only the women of Actimed, but all #WomenAndGirlsInScience!


Ahead of World Cancer Day, join us as we cast a light on cancer cachexia. For a long time, cachexia has been recognized as an adverse effect of cancer and it has been estimated that this devastating wasting disease affects 50–80% of cancer patients and accounts for up to 20% of cancer deaths. 
 
Other than supportive care, no globally approved products are available for this patient population so there remains an important unmet need for effective new treatments.
 
At Actimed, our work is rooted in our mission to bring innovation to the forefront of cancer cachexia treatment and redefine the standard of care for this under-served and vulnerable patient population.
 
Learn more about our work as we transform hope into action: actimedtherapeutics.com 
 
Learn more about #WorldCancerDay : www.worldcancerday.org
 
#CancerCachexia

We’re pleased to see Actimed featured in BioWorld following an interview by Caroline Richards with our CEO Robin Bhattacherjee. The article highlights our achievements in seeking to develop a treatment for cancer cachexia and outlines our further plans for our lead asset, s-pindolol benzoate, in the treatment of this devastating condition. 
 
For subscribers to BioWorld, read the article to learn more about our strides in advancing the fight against cancer cachexia: https://lnkd.in/ebGaJKiQ 

#CancerCachexia #BiotechFinancing #ClinicalDevelopment 

We are delighted to welcome Martin Walton as Chief Financial Officer at Actimed. 
 
Martin is a highly experienced advisor in the life sciences sector and has held a number of executive positions, completing transactions with over 25 companies and raising over £1bn in capital.
 
We believe Martin’s extensive experience and multidisciplinary skills set will play an important role in the continuing development of Actimed.

COM:ACTIMEDTHERAPEUTICS

Actimed Therapeutics

Financials Not Available